Suppr超能文献

丝氨酸蛋白酶抑制剂在血栓形成、止血和纤维蛋白溶解中的作用

Serpins in thrombosis, hemostasis and fibrinolysis.

作者信息

Rau J C, Beaulieu L M, Huntington J A, Church F C

机构信息

Department of Pathology and Laboratory Medicine, Carolina Cardiovascular Biology Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599-7035, USA.

出版信息

J Thromb Haemost. 2007 Jul;5 Suppl 1(Suppl 1):102-15. doi: 10.1111/j.1538-7836.2007.02516.x.

Abstract

Hemostasis and fibrinolysis, the biological processes that maintain proper blood flow, are the consequence of a complex series of cascading enzymatic reactions. Serine proteases involved in these processes are regulated by feedback loops, local cofactor molecules, and serine protease inhibitors (serpins). The delicate balance between proteolytic and inhibitory reactions in hemostasis and fibrinolysis, described by the coagulation, protein C and fibrinolytic pathways, can be disrupted, resulting in the pathological conditions of thrombosis or abnormal bleeding. Medicine capitalizes on the importance of serpins, using therapeutics to manipulate the serpin-protease reactions for the treatment and prevention of thrombosis and hemorrhage. Therefore, investigation of serpins, their cofactors, and their structure-function relationships is imperative for the development of state-of-the-art pharmaceuticals for the selective fine-tuning of hemostasis and fibrinolysis. This review describes key serpins important in the regulation of these pathways: antithrombin, heparin cofactor II, protein Z-dependent protease inhibitor, alpha(1)-protease inhibitor, protein C inhibitor, alpha(2)-antiplasmin and plasminogen activator inhibitor-1. We focus on the biological function, the important structural elements, their known non-hemostatic roles, the pathologies related to deficiencies or dysfunction, and the therapeutic roles of specific serpins.

摘要

止血和纤维蛋白溶解是维持正常血流的生物学过程,是一系列复杂的级联酶促反应的结果。参与这些过程的丝氨酸蛋白酶受反馈回路、局部辅因子分子和丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制因子)的调节。凝血、蛋白C和纤维蛋白溶解途径所描述的止血和纤维蛋白溶解中蛋白水解和抑制反应之间的微妙平衡可能会被打破,从而导致血栓形成或异常出血的病理状况。医学利用丝氨酸蛋白酶抑制因子的重要性,使用治疗药物来操纵丝氨酸蛋白酶抑制因子-蛋白酶反应,以治疗和预防血栓形成和出血。因此,研究丝氨酸蛋白酶抑制因子、它们的辅因子及其结构-功能关系对于开发用于选择性微调止血和纤维蛋白溶解的先进药物至关重要。本综述描述了在这些途径调节中重要的关键丝氨酸蛋白酶抑制因子:抗凝血酶、肝素辅因子II、蛋白Z依赖性蛋白酶抑制剂、α1-蛋白酶抑制剂、蛋白C抑制剂、α2-抗纤溶酶和纤溶酶原激活物抑制剂-1。我们重点关注其生物学功能、重要的结构元件、已知的非止血作用、与缺乏或功能障碍相关的病理学以及特定丝氨酸蛋白酶抑制因子的治疗作用。

相似文献

1
Serpins in thrombosis, hemostasis and fibrinolysis.
J Thromb Haemost. 2007 Jul;5 Suppl 1(Suppl 1):102-15. doi: 10.1111/j.1538-7836.2007.02516.x.
2
Serpin regulation of fibrinolytic system: implications for therapeutic applications in cardiovascular diseases.
Cardiovasc Hematol Agents Med Chem. 2014;12(2):91-125. doi: 10.2174/1871525712666141106095927.
3
Mechanisms of glycosaminoglycan activation of the serpins in hemostasis.
J Thromb Haemost. 2003 Jul;1(7):1535-49. doi: 10.1046/j.1538-7836.2003.00305.x.
4
Role of heparin and non heparin binding serpins in coagulation and angiogenesis: A complex interplay.
Arch Biochem Biophys. 2016 Aug 15;604:128-42. doi: 10.1016/j.abb.2016.06.018. Epub 2016 Jun 29.
5
Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.
Front Cardiovasc Med. 2022 May 3;9:878199. doi: 10.3389/fcvm.2022.878199. eCollection 2022.
7
Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders.
Front Cardiovasc Med. 2021 Jan 7;7:622778. doi: 10.3389/fcvm.2020.622778. eCollection 2020.
9
Fibrinolysis inhibitors.
Clin Lab Sci. 1997 Jul-Aug;10(4):212-8.
10
"Super" SERPINs-A stabilizing force against fibrinolysis in thromboinflammatory conditions.
Front Cardiovasc Med. 2023 Apr 19;10:1146833. doi: 10.3389/fcvm.2023.1146833. eCollection 2023.

引用本文的文献

2
A facultative plasminogen-independent thrombolytic enzyme from Sipunculus nudus.
Nat Commun. 2025 Apr 24;16(1):3852. doi: 10.1038/s41467-025-58915-y.
3
Induced clustering of SHP2-depleted tumor cells in vascular islands restores sensitivity to MEK/ERK inhibition.
J Clin Invest. 2025 Mar 25;135(10). doi: 10.1172/JCI181609. eCollection 2025 May 15.
4
Conditional Overexpression of Serpine2 Promotes Hair Cell Regeneration from Lgr5+ Progenitors in the Neonatal Mouse Cochlea.
Adv Sci (Weinh). 2025 May;12(18):e2412653. doi: 10.1002/advs.202412653. Epub 2025 Mar 17.
5
The landscape of plasma proteomic links to human organ imaging.
medRxiv. 2025 Jan 15:2025.01.14.25320532. doi: 10.1101/2025.01.14.25320532.
6
Aging platelets shift their hemostatic properties to inflammatory functions.
Blood. 2025 Apr 3;145(14):1568-1582. doi: 10.1182/blood.2024024901.
7
Exercise, Neuroprotective Exerkines, and Parkinson's Disease: A Narrative Review.
Biomolecules. 2024 Sep 30;14(10):1241. doi: 10.3390/biom14101241.
8
A Protease from Moringa oleifera Lam. Exhibits In-vitro Blood Clot Solubilization and Fibrin Hydrolysis.
Protein J. 2024 Aug;43(4):923-934. doi: 10.1007/s10930-024-10222-z. Epub 2024 Jul 28.

本文引用的文献

1
Clinical impact of in-stent late loss after drug-eluting coronary stent implantation.
Eur Heart J. 2007 Jul;28(13):1583-91. doi: 10.1093/eurheartj/ehl423. Epub 2007 Feb 8.
3
Coagulation 2006: a modern view of hemostasis.
Hematol Oncol Clin North Am. 2007 Feb;21(1):1-11. doi: 10.1016/j.hoc.2006.11.004.
4
Agents to control bleeding show promise.
JAMA. 2007 Jan 24;297(4):349-50. doi: 10.1001/jama.297.4.349.
5
Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis.
Blood. 2007 May 15;109(10):4258-63. doi: 10.1182/blood-2006-08-040774. Epub 2007 Jan 23.
6
Detecting antithrombin deficiency may be a difficult task--more than one test is necessary.
J Thromb Haemost. 2007 Mar;5(3):617-8. doi: 10.1111/j.1538-7836.2007.02395.x. Epub 2007 Jan 10.
7
Platelets as immune cells: bridging inflammation and cardiovascular disease.
Circ Res. 2007 Jan 5;100(1):27-40. doi: 10.1161/01.RES.0000252802.25497.b7.
8
Heparin cofactor II modulates the response to vascular injury.
Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):454-60. doi: 10.1161/01.ATV.0000256471.22437.88. Epub 2006 Dec 28.
9
Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents.
Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):400-6. doi: 10.1161/01.ATV.0000254677.12861.b8. Epub 2006 Dec 7.
10
Identification of the circadian clock-regulated E-box element in the mouse plasminogen activator inhibitor-1 gene.
J Thromb Haemost. 2007 Feb;5(2):428-31. doi: 10.1111/j.1538-7836.2007.02348.x. Epub 2006 Nov 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验